Skip to main content

Table 1 Clinical inputs at 3 months

From: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

 

SEC 150

SEC 300

CER P

ETN

ADA

INF

GOL

UST

APR

PsARC response [36] (% of patients)

Biologic Naïve a

59.82%

51.18%

73.61%

70.91%

62.84%

78.65%

79.96%

73.61%

73.61%

Biologic experienced b

N/A

82.45%

67.89%

68.38%

51.72%

67.73%

59.90%

60.87%

46.04%

PASI response [36] (% of patients)

PASI score

Biologic Naïve c

PASI < 50

24.70%

21.94%

26.30%

26.30%

30.00%

13.35%

39.43%

26.30%

26.30%

PASI 50-74

22.73%

21.92%

23.12%

23.12%

23.79%

17.84%

24.31%

23.12%

23.12%

PASI 75-89

23.00%

23.39%

22.71%

22.71%

21.90%

23.22%

19.23%

22.71%

22.71%

PASI 90-99

29.57%

32.76%

27.87%

27.87%

24.31%

45.58%

17.03%

27.87%

27.87%

PASI 100

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

 

Biologic experienced d

PASI < 50

N/A

19.63%

74.10%

74.48%

58.98%

48.84%

63.39%

58.00%

80.40%

PASI 50-74

N/A

16.87%

11.80%

11.72%

12.47%

8.83%

12.86%

12.31%

10.11%

PASI 75-89

N/A

23.01%

8.91%

8.76%

13.96%

14.30%

12.64%

14.17%

6.47%

PASI 90-99

N/A

40.49%

5.20%

5.04%

14.60%

28.03%

10.82%

15.52%

3.01%

PASI 100

N/A

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

Change in HAQe#

Biologic Naïve

Regardless of PsARC response

− 0.4780

− 0.5780

− 0.2410

− 0.5259

− 0.3579

− 0.5578

− 0.3629

− 0.1988

− 0.2363

Given PsARC response

− 0.5430

− 0.6880

− 0.3950

− 0.6400

− 0.4900

− 0.6600

− 0.4400

− 0.3950

− 0.3950

Given no PsARC response

− 0.2310

− 0.2500

0.0000

− 0.2000

− 0.1400

− 0.2000

− 0.0600

0.0000

0.0000

Biologic experienced e

Regardless of PsARC response

N/A

− 0.5360

− 0.2410

− 0.5259

− 0.3579

− 0.5578

− 0.3629

− 0.1988

− 0.2363

Given PsARC response

N/A

− 0.5360

− 0.3950

− 0.6400

− 0.4900

− 0.6600

− 0.4400

− 0.3950

− 0.3950

Given no PsARC response

N/A

− 0.3270

0.0000

− 0.2000

− 0.1400

− 0.2000

− 0.0600

0.0000

0.0000

  1. ADA, adalimumab; APR, apremilast, CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; PsARC, Psoriatic arthritis response criteria; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; UST, ustekinumab
  2. aBiologic-naive data for certolizumab pegol and ustekinumab were not available and were assumed equivalent to be average of other biologics in the NMA. Trials for etanercept 50 mg once weekly did not link into the network, thus data for etanercept 25 mg twice weekly were used. Data for experienced population was lacking and was computed by applying a reduction to mixed population. Secukinumab: 0.43% reduction, other Tumor Necrosis Factor-alpha inhibitor (TNFi): 10.1%
  3. bBiologic-experienced data for ustekinumab were not available and were assumed equivalent to average of other biologics in the NMA. Trials for etanercept 50 mg once weekly did not link into the network, thus data for etanercept 25 mg twice weekly were used
  4. cBiologic-naive data for certolizumab pegol, etanercept, golimumab and ustekinumab were not available and were assumed equivalent to the average of other biologics in the network meta-analysis (NMA). Secukinumab 150 mg was evaluated in biologic-naïve population without moderate to severe psoriasis and secukinumab 300 mg was evaluated in biologic-naïve patients with moderate to severe psoriasis
  5. dData for experienced population was lacking and was computed by applying a reduction to mixed population. For Sec and other Tumor Necrosis Factor-alpha inhibitor (TNFi): PASI 50: 1.34% and 43.08% reduction, PASI 75: 6.84% and 40.64% reduction, PASI 90: 6.67% and 41.86%
  6. eSecukinumab 150 mg was evaluated in biologic-naïve population without moderate to severe psoriasis and secukinumab 300 mg was evaluated in biologic-naïve patients with moderate to severe psoriasis. For biologic-experienced patients, data were assumed equivalent to that of mixed population
  7. #Sources: Biologic experienced, regardless of PsARC response—SEC 150 and SEC 300 from FUTURE 2 trial; CER P set equal to placebo; ETN, ADA, INF, GOL, UST, and APR estimated from changes in HAQ with and without PsARC response and PsARC response probabilities; biologic experienced, given PsARC response—SEC 150, SEC 300 from FUTURE 2 trial; CER P, UST, and APR set equal to placebo; ETN, ADA, INF, and GOL from Cawson et al. [31]; biologic experienced, given no PsARC response—SEC 150 and SEC 300 from FUTURE 2 trial; CER P, UST, and APR set equal to placebo; ETN, ADA, INF, and GOL from Cawson et al. [31]; Biologic naïve, regardless of PsARC response—SEC 150, SEC 300, and placebo from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, and APR set equal to biologic naïve or experienced, regardless of PsARC response; biologic naïve, given PsARC response—SEC 150, SEC 300 from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, and APR set equal to biologic naïve or experienced, given PsARC response; biologic naïve, given no PsARC response—SEC 150 and SEC 300 from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, APR set equal to biologic naïve or experienced, given no PsARC response
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us